<code id='434E82B7C9'></code><style id='434E82B7C9'></style>
    • <acronym id='434E82B7C9'></acronym>
      <center id='434E82B7C9'><center id='434E82B7C9'><tfoot id='434E82B7C9'></tfoot></center><abbr id='434E82B7C9'><dir id='434E82B7C9'><tfoot id='434E82B7C9'></tfoot><noframes id='434E82B7C9'>

    • <optgroup id='434E82B7C9'><strike id='434E82B7C9'><sup id='434E82B7C9'></sup></strike><code id='434E82B7C9'></code></optgroup>
        1. <b id='434E82B7C9'><label id='434E82B7C9'><select id='434E82B7C9'><dt id='434E82B7C9'><span id='434E82B7C9'></span></dt></select></label></b><u id='434E82B7C9'></u>
          <i id='434E82B7C9'><strike id='434E82B7C9'><tt id='434E82B7C9'><pre id='434E82B7C9'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:knowledge    - browse:97
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus